Why the study?
Intravenous thrombolysis is restricted by stringent contraindications causing disparities between drug labels and guidelines, prompting increasing off-label use that requires evaluation of safety and efficacy.
Does off-label use of intravenous thrombolysis improve outcomes in patients with acute ischemic stroke?
Population
Patients with acute ischemic stroke or conditions mimicking acute cerebral ischemia
Comparison
Off-label use of IVT vs standard criteria or alternative conditions
Design
Narrative review
Authors
Loading...
May inform cautious off-label IVT decisions in select AIS subgroups; leaves open need for dedicated RCTs to confirm net benefit.
Does off-label use of intravenous thrombolysis improve outcomes in patients with acute ischemic stroke?
This narrative review provides practical recommendations and guidance on the risks and benefits of off-label intravenous thrombolysis in complex presentations of acute ischemic stroke.
Tsivgoulis et al. (2021) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: